文献速递泌尿男性生殖肿瘤

局限不利风险前列腺癌男性接受放疗与放疗加雄激素剥夺治疗的全因死亡率替代终点:一项随机临床试验的二次分析

Surrogate End Points for All-Cause Mortality in Men With Localized Unfavorable-Risk Prostate Cancer Treated With Radiation Therapy vs Radiation Therapy Plus Androgen Deprivation Therapy: A Secondary Analysis of a Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2017-01-01

该随机临床试验二次分析纳入157例局限不利风险前列腺癌且合并症极少或无的患者,随机接受放疗或放疗后6个月雄激素剥夺治疗,中位随访16.49个月。结果显示PSA最低值>0.5 ng/mL、PSA倍增时间<9个月和PSA失败间隔<30个月满足全部4项Prentice替代终点标准,而PSA失败不满足。

要点

  • PSA最低值>0.5 ng/mL、PSA倍增时间<9个月和PSA失败间隔<30个月是全因死亡率的替代终点。
  • PSA失败未满足Prentice替代终点标准。
  • 三个成功替代终点的治疗效应比例分别为103.86%、43.09%和41.26%。

核心结论

  • 放疗和雄激素剥夺治疗后PSA最低值>0.5 ng/mL似乎可在PSA失败前识别高死亡风险男性。
  • 该指标可用于在PSA最低值时筛选男性进入评估挽救性雄激素剥夺治疗联合或不联合延长生存药物对生存影响的随机试验。

研究设计与样本

  • 随机临床试验的二次分析,纳入206例局限不利风险前列腺癌男性,随机接受单纯放疗或放疗后6个月雄激素剥夺治疗,中位随访16.62年。
  • 本分析纳入157例合并症极少或无的患者,中位随访16.49个月。
  • 患者来自1995年12月1日至2001年4月15日期间在哈佛附属学术医院或相关社区医院就诊者。

主要发现

  • PSA最低值>0.5 ng/mL的调整风险比(aHR)为1.72(95%CI 1.17-2.52,P=.01)。
  • PSA倍增时间<9个月的aHR为2.06(95%CI 1.29-3.28,P=.003)。
  • PSA失败间隔<30个月的aHR为1.76(95%CI 1.06-2.92,P=.03)。
  • PSA失败未满足Prentice替代终点标准。
  • 三个成功替代终点的治疗效应比例分别为103.86%、43.09%和41.26%。

关键数值与推荐

  • PSA最低值>0.5 ng/mL、PSA倍增时间<9个月和PSA失败间隔<30个月满足全部4项Prentice替代终点标准。

临床怎么用

  • 放疗和雄激素剥夺治疗后PSA最低值>0.5 ng/mL似乎可在PSA失败前识别高死亡风险男性。
  • 该指标可用于在PSA最低值时筛选男性进入评估挽救性雄激素剥夺治疗联合或不联合延长生存药物对生存影响的随机试验。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Several surrogates for prostate cancer-specific mortality satisfying the Prentice criteria exist, but whether these are surrogates for all-cause mortality, and how their performance compares, is unknown. OBJECTIVE: To ascertain and compare the performance of 4 candidate surrogates (prostate-specific antigen [PSA] failure, PSA nadir >0.5 ng/mL, PSA doubling time <9 months, and interval to PSA failure <30 months) for all-cause mortality using the proportion of treatment-effect metric. DESIGN, SETTING, AND PARTICIPANTS: For this randomized clinical trial, 206 men with unfavorable-risk prostate cancer who were seen at a Harvard-affiliated academic hospital or an associated community hospital between December 1, 1995, to April 15, 2001, were identified, randomized to radiation therapy alone or radiation therapy followed by 6 months of androgen deprivation therapy, and followed for a median 16.62 years. This analysis looks at the subgroup of 157 men with minimal comorbidities or no comorbidity (median follow-up, 16.49 months). INTERVENTIONS: Patients were previously randomized to receive radiation therapy or radiation and 6 months of androgen deprivation therapy. MAIN OUTCOMES AND MEASURES: Risk of all-cause mortality. RESULTS: Overall, a cohort of 157 men (median [interquartile range] age, 72.43 [68.75-75.53]) with unfavorable-risk prostate cancer and minimal or no comorbidities were selected for this study. Three tested metrics met all 4 Prentice criteria for surrogacy for the surrogate covariate in the adjusted model for all-cause mortality: PSA nadir greater than 0.5 ng/mL (adjusted hazard ratio [aHR], 1.72; 95% CI, 1.17-2.52; P = .01), PSA doubling time less than 9 months (aHR, 2.06; 95% CI, 1.29-3.28; P = .003), and interval to PSA failure less than 30 months (aHR, 1.76; 95% CI, 1.06-2.92; P = .03); while PSA failure did not. For the 3 successful surrogates, the proportion of treatment effect values were 103.86%, 43.09%, and 41.26%, respectively. CONCLUSIONS AND RELEVANCE: A PSA nadir value of greater than 0.5 ng/mL following radiation and androgen deprivation therapy appears to identify men prior to PSA failure who are at high-risk for death. This could be used to select men for entry at the time of PSA nadir onto randomized trials evaluating the impact on survival of salvage androgen deprivation therapy with or without agents shown to prolong survival in men with castrate-resistant metastatic prostate cancer. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00116220.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Royce TJ, Chen MH, Wu J, et al. Surrogate End Points for All-Cause Mortality in Men With Localized Unfavorable-Risk Prostate Cancer Treated With Radiation Therapy vs Radiation Therapy Plus Androgen Deprivation Therapy: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2017. PMID: 28097317. doi:10.1001/jamaoncol.2016.5983

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。